Media coverage about Tyme Technologies (NASDAQ:TYME) has been trending somewhat positive on Friday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tyme Technologies earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.5083099784639 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Tyme Technologies (NASDAQ:TYME) traded up $0.17 during trading on Friday, reaching $6.91. 164,400 shares of the company’s stock traded hands, compared to its average volume of 121,238. Tyme Technologies has a twelve month low of $2.01 and a twelve month high of $9.50. The company has a market capitalization of $617.21, a price-to-earnings ratio of -43.19 and a beta of -42.35.
Several brokerages have issued reports on TYME. BidaskClub upgraded shares of Tyme Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Canaccord Genuity began coverage on shares of Tyme Technologies in a research report on Wednesday, January 3rd. They set a “buy” rating for the company. HC Wainwright began coverage on shares of Tyme Technologies in a research report on Friday, December 15th. They set a “buy” rating and a $8.00 target price for the company. Finally, Evercore ISI began coverage on shares of Tyme Technologies in a research report on Friday, November 17th. They set an “outperform” rating and a $7.00 target price for the company.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-tyme-technologies-tyme-stock-price.html.
About Tyme Technologies
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
What are top analysts saying about Tyme Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tyme Technologies and related companies.